AU2001273661A1 - Methods of screening for alzheimer's disease - Google Patents

Methods of screening for alzheimer's disease

Info

Publication number
AU2001273661A1
AU2001273661A1 AU2001273661A AU7366101A AU2001273661A1 AU 2001273661 A1 AU2001273661 A1 AU 2001273661A1 AU 2001273661 A AU2001273661 A AU 2001273661A AU 7366101 A AU7366101 A AU 7366101A AU 2001273661 A1 AU2001273661 A1 AU 2001273661A1
Authority
AU
Australia
Prior art keywords
alzheimer
screening
disease
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001273661A
Inventor
Jonathan L. Haines
Margaret Pericak-Vance
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of AU2001273661A1 publication Critical patent/AU2001273661A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/40—Population genetics; Linkage disequilibrium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
AU2001273661A 2000-06-30 2001-06-29 Methods of screening for alzheimer's disease Abandoned AU2001273661A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21515100P 2000-06-30 2000-06-30
US60215151 2000-06-30
PCT/US2001/041224 WO2002002000A2 (en) 2000-06-30 2001-06-29 Methods of screening for alzheimer's disease

Publications (1)

Publication Number Publication Date
AU2001273661A1 true AU2001273661A1 (en) 2002-01-14

Family

ID=22801869

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001273661A Abandoned AU2001273661A1 (en) 2000-06-30 2001-06-29 Methods of screening for alzheimer's disease

Country Status (3)

Country Link
US (1) US20040053251A1 (en)
AU (1) AU2001273661A1 (en)
WO (1) WO2002002000A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001092576A1 (en) * 2000-05-26 2001-12-06 Duke University Methods of screening for parkinson's disease
US20040014109A1 (en) * 2002-05-23 2004-01-22 Pericak-Vance Margaret A. Methods and genes associated with screening assays for age at onset and common neurodegenerative diseases
WO2004005534A2 (en) * 2002-07-08 2004-01-15 Duke University Screening for alzheimer's disease
US20060246437A1 (en) * 2003-07-11 2006-11-02 Pericak-Vance Margaret A Genetic susceptibility genes for asthma and atopy and asthma-related and atopic-related phenotypes
US20060068428A1 (en) * 2003-11-03 2006-03-30 Duke University Identification of genetic markers associated with parkinson disease
US20050191652A1 (en) * 2003-11-03 2005-09-01 Vance Jeffery M. Identification of genetic forms of a gene that leads to high risk for parkinson disease
US7790390B2 (en) * 2004-10-27 2010-09-07 Duke University Methods for identifying an individual at increased risk of developing coronary artery disease
US7807465B2 (en) 2004-10-27 2010-10-05 Duke University Methods for identifying an individual at increased risk of developing coronary artery disease
US20060200878A1 (en) 2004-12-21 2006-09-07 Linda Lutfiyya Recombinant DNA constructs and methods for controlling gene expression
US7771937B2 (en) * 2005-05-20 2010-08-10 University Of Washington Methods for predicting late onset Alzheimer disease in an individual
US20070148661A1 (en) * 2005-07-19 2007-06-28 Duke University LSAMP Gene Associated With Cardiovascular Disease
US20090226420A1 (en) * 2005-11-10 2009-09-10 Elizabeth Hauser Methods of Determining the Risk of Developing Coronary Artery Disease
CN103169949A (en) * 2005-11-16 2013-06-26 潘塔希生物科学股份有限公司 Pharmaceutical composition for treating or preventing ovarian cancer
MX2009001937A (en) * 2006-08-21 2009-04-30 Novartis Ag Biomarkers for alzheimer's disease progression.
EP2191014B1 (en) 2007-08-13 2013-04-03 Baxter International Inc. Ivig modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease
US10395759B2 (en) 2015-05-18 2019-08-27 Regeneron Pharmaceuticals, Inc. Methods and systems for copy number variant detection

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374525A (en) * 1992-09-30 1994-12-20 University Of Utah Research Foundation Methods to determine predisposition to hypertension and association of variant angiotensinogen gene and hypertension
DE625212T1 (en) * 1992-10-13 2000-11-02 Univ Durham METHOD FOR DISCOVERING DISEASE OF ALZHEIMER.
US5449604A (en) * 1992-10-21 1995-09-12 University Of Washington Chromosome 14 and familial Alzheimers disease genetic markers and assays
US5879884A (en) * 1994-12-29 1999-03-09 Peroutka; Stephen J. Diagnosis of depression by linkage of a polymorphic marker to a segment of chromosome 19P13 bordered by D19S247 and D19S394
US5986054A (en) * 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
US5958684A (en) * 1995-10-02 1999-09-28 Van Leeuwen; Frederik Willem Diagnosis of neurodegenerative disease
US6108635A (en) * 1996-05-22 2000-08-22 Interleukin Genetics, Inc. Integrated disease information system
US5922556A (en) * 1997-07-03 1999-07-13 The Trustees Of Columbia University In The City Of New York Parkinson's disease tests
US6342350B1 (en) * 1997-09-05 2002-01-29 The General Hospital Corporation Alpha-2-macroglobulin diagnostic test
US20020037508A1 (en) * 2000-01-19 2002-03-28 Michele Cargill Human single nucleotide polymorphisms
WO2001092576A1 (en) * 2000-05-26 2001-12-06 Duke University Methods of screening for parkinson's disease
US20040014109A1 (en) * 2002-05-23 2004-01-22 Pericak-Vance Margaret A. Methods and genes associated with screening assays for age at onset and common neurodegenerative diseases
US20060068428A1 (en) * 2003-11-03 2006-03-30 Duke University Identification of genetic markers associated with parkinson disease
US20050191652A1 (en) * 2003-11-03 2005-09-01 Vance Jeffery M. Identification of genetic forms of a gene that leads to high risk for parkinson disease
US7807465B2 (en) * 2004-10-27 2010-10-05 Duke University Methods for identifying an individual at increased risk of developing coronary artery disease

Also Published As

Publication number Publication date
WO2002002000A2 (en) 2002-01-10
WO2002002000A3 (en) 2002-06-20
US20040053251A1 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
AU2001233299A1 (en) Methods for treating alzheimer's disease
AU2002219824A1 (en) Compositions and methods for diagnosing alzheimer's disease
AU2001273132A1 (en) Compounds to treat alzheimer's disease
AU1407399A (en) Treatment for alzheimer's disease
AU7708498A (en) Nematode model for alzheimer's disease
AU2610901A (en) Predictive diagnostic for alzheimer's disease
AU2865000A (en) Alpha-2-macroglobulin therapies and drug screening methods for alzheimer's disease
AU2001273661A1 (en) Methods of screening for alzheimer's disease
AU2001264950A1 (en) Methods of screening for parkinson's disease
AU2001236592A1 (en) Methods for diagnosis of alzheimer's disease
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
AU2002246490A1 (en) Method of treating parkinson's disease
AU1405899A (en) Treatment for alzheimer's disease
AUPR202400A0 (en) Method of screening for inhibitors of alzheimer's disease
AU2003251962A1 (en) Screening for alzheimer's disease
AU2003299101A1 (en) Compounds for the treatment of alzheimer's disease
AU2002242348A1 (en) Process for obtaining 3'-epilutein
AU2002341044A1 (en) Methods for detecting parkinson's disease
AU2001273675A1 (en) Methods and assays for diagnosing alzheimer's disease
AU2001267826A1 (en) Remedies for alzheimer's disease
AU2001258569A1 (en) Alzheimer's disease assay
AU2001274413A1 (en) Synthesis procedure for biphenylimidazolyl-(1)-phenylmethane and related compounds
AU2002364885A1 (en) Alzheimer's disease model
AU2001255234A1 (en) Cellular calcium responce for diagnosis of alzheimer's disease
AU2001255439A1 (en) Method of treating alzheimer's disease